GlaxoSmithKline plc (ADR) (GSK), Merck & Co., Inc. (MRK): Why You Should Care About This Diabetes Drug Saga

New precedence?

If the FDA follows the panel’s advice, we can add it to the growing evidence that the agency is lightening up. That’s good news for companies such as Sarepta Therapeutics Inc (NASDAQ:SRPT), that’s trying to get its Duchenne muscular dystrophy drug, eteplirsen, approved with very little data and Amarin Corporation plc (ADR) (NASDAQ:AMRN), which is requesting an expansion of the number of treatable patients for its fish oil Vascepa before clinical outcome data is available.

The article Why You Should Care About This Diabetes Drug Saga originally appeared on and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.